Bone marrow cancer is a group of cancers that start in the soft, spongy tissue inside your bones where blood cells are made. The three main types are leukemia, multiple myeloma, and lymphoma. Each affects a different type of blood cell, but they share a common problem: abnormal cells multiply out of control inside the marrow, crowding out the healthy cells your body needs to function.
How Bone Marrow Normally Works
Your bone marrow is essentially a blood cell factory. It produces red blood cells that carry oxygen, white blood cells that fight infection, and platelets that help your blood clot. This process, called hematopoiesis, runs continuously throughout your life. Every day, your marrow generates billions of new cells to replace old ones.
When cancer develops in the marrow, immature or defective cells begin proliferating uncontrollably. These cells fail to mature properly, so they can’t do their jobs. Worse, they physically take up space that healthy cells need, which is why bone marrow cancers cause such wide-ranging symptoms. A problem in the marrow ripples outward to affect nearly every system in the body.
The Three Main Types
Leukemia
Leukemia affects white blood cells. Abnormal white blood cells accumulate in the marrow and spill into the bloodstream, where they crowd out normal cells. Leukemia comes in acute forms (fast-growing, with immature cells that can’t function) and chronic forms (slower-growing, with cells that partially mature). One well-known genetic driver is the Philadelphia chromosome, an abnormal version of chromosome 22 created when pieces of chromosomes 9 and 22swap places. The resulting fusion gene produces a protein that causes immature white blood cells to grow uncontrollably. This abnormality appears in nearly all cases of chronic myelogenous leukemia and some cases of acute leukemia.
Multiple Myeloma
Multiple myeloma targets plasma cells, a specialized type of white blood cell that produces antibodies to fight infection. In myeloma, cancerous plasma cells build up in the bone marrow and produce abnormal proteins instead of useful antibodies. Over time, these cells damage bones, kidneys, and the immune system. A diagnosis typically requires finding 10% or more abnormal plasma cells in a bone marrow sample, plus evidence of organ damage or specific biomarkers of malignancy.
The five-year relative survival rate for multiple myeloma is about 64%, based on recent data from the National Cancer Institute’s SEER program. When the disease is caught while still localized, that number rises to roughly 82%.
Lymphoma
Lymphoma is a cancer of the lymphatic system, which includes lymph nodes, the spleen, and the bone marrow. While lymphoma often starts in the lymph nodes, it can originate in or spread to the marrow. Hodgkin lymphoma and non-Hodgkin lymphoma are the two broad categories, each with many subtypes that vary in aggressiveness and treatment approach.
Symptoms to Recognize
Bone marrow cancers can be sneaky in the early stages. Multiple myeloma, for instance, may cause no symptoms at all initially. When signs do appear, they tend to reflect the disruption of normal blood cell production and, in myeloma’s case, direct damage to bones and organs.
Common symptoms include:
- Bone pain, particularly in the spine, chest, or hips
- Persistent fatigue, caused by low red blood cell counts (anemia)
- Frequent or severe infections, from a shortage of functional white blood cells
- Easy bruising or unusual bleeding, due to low platelet counts
- Unexplained weight loss and loss of appetite
- Confusion or mental fogginess, often linked to high calcium levels in the blood
- Excessive thirst and frequent urination
In multiple myeloma specifically, doctors look for a pattern of organ damage known by the acronym CRAB: elevated calcium, renal (kidney) problems, anemia, and bone lesions. These four signs together are strong indicators that myeloma has progressed enough to require treatment. Bone lesions must show actual destruction of at least 5 mm in size on imaging to count toward the diagnosis.
How It’s Diagnosed
Blood tests often provide the first clue. Abnormal blood counts, unusual proteins, or elevated calcium can all point toward a marrow problem. But confirming the diagnosis requires looking directly at the marrow itself.
A bone marrow exam actually involves two procedures, usually done at the same time. In an aspiration, a thin needle withdraws a small amount of the liquid portion of the marrow. In a biopsy, a specially designed needle removes a tiny cylindrical core of the solid marrow tissue. Together, these samples let a specialist called a hematopathologist evaluate whether the marrow is producing healthy blood cells or harboring abnormal ones. The samples also undergo genetic testing to identify chromosomal abnormalities like the Philadelphia chromosome, which helps determine the exact type of cancer and guides treatment decisions.
The procedure is typically done on the back of the hip bone. Most people describe it as uncomfortable, with a deep pressure or brief sharp pain that lasts seconds. The entire process takes about 30 minutes.
Treatment Approaches
Treatment varies significantly depending on which type of bone marrow cancer you have, how aggressive it is, and your overall health. But several core strategies are used across the board.
Chemotherapy remains a foundation of treatment for most bone marrow cancers, often combined with other therapies. For multiple myeloma, treatment plans commonly pair chemotherapy with drugs that modulate the immune system or block specific proteins the cancer cells rely on. For leukemia, the intensity of chemotherapy depends on whether the disease is acute or chronic.
Stem Cell Transplants
Stem cell transplants offer the possibility of rebuilding a healthy marrow after high-dose treatment destroys the diseased one. There are two main types. In an autologous transplant, your own stem cells are collected before treatment, stored, and then returned to your body afterward. The advantage is perfect compatibility, though there’s a small risk that some cancer cells get collected along with healthy ones.
In an allogeneic transplant, stem cells come from a donor, either a family member or an unrelated person whose cells closely match yours. This carries a unique benefit: the donor’s immune cells can actively attack remaining cancer cells, an effect called graft-versus-tumor. However, it also carries a serious risk called graft-versus-host disease, where the donor’s immune cells attack your healthy tissues.
A variation called a mini-transplant uses lower doses of chemotherapy. It doesn’t destroy all of your blood-forming cells but suppresses your immune system enough to accept donor cells while still killing some cancer. For multiple myeloma, tandem transplants are sometimes used, involving two rounds of high-dose chemotherapy each followed by a stem cell transplant, spaced weeks or months apart.
CAR-T Cell Therapy
One of the newer treatment options involves engineering your own immune cells to recognize and attack cancer. In CAR-T cell therapy, white blood cells are removed from your blood, genetically modified in a lab to target specific proteins on cancer cells, and then infused back into your body. The FDA has approved CAR-T therapies for multiple myeloma, certain types of leukemia, and several forms of lymphoma. This treatment is typically reserved for cancer that has returned after other treatments or hasn’t responded to them.
What Affects Survival and Outlook
Outcomes vary enormously depending on the specific cancer, its genetic profile, and how early it’s caught. Chronic leukemias can often be managed for years or even decades with targeted therapy. Acute leukemias are more aggressive but can sometimes be cured, particularly in younger patients.
For multiple myeloma, the outlook has improved substantially over the past two decades as new treatments have become available. The overall five-year survival of 64% masks significant variation: patients diagnosed at an early, localized stage have survival rates above 80%, while those with more advanced disease at diagnosis are closer to 63%. Genetic features of the cancer cells also matter. Certain chromosomal abnormalities carry a worse prognosis, which is one reason genetic testing at diagnosis is so important.
Age and general fitness play a role too. Younger, healthier patients can tolerate more aggressive treatments like stem cell transplants, which tend to produce better long-term results. For older adults or those with other health conditions, treatment plans focus on controlling the disease and maintaining quality of life, often achieving years of stable remission with less intensive approaches.